Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ARVN with free AI briefings, catalyst countdowns, and dilution alerts.

ARVN · ARVINAS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$558.4M Cash on Hand
57.1mo Cash Runway
10.2% Short Interest
$14 Analyst Target (13)
Follow ARVN by email Get an email when ARVN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ARVN, unsubscribe in one click. Privacy

📣 What ARVN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Vepdegestrant (ARV-471) Advanced Breast Cancer Phase 3 · NCT05654623 Active not recruiting
SOC Advanced Solid Tumor Phase 1/2 · NCT07749586 Recruiting
Atirmociclib Breast Cancer Phase 1/2 · NCT06206837 Active not recruiting
Samuraciclib Breast Cancer Phase 1/2 · NCT06125522 Terminated
KRAS G12D Degrader ARV-806 KRAS G12D Mutation Phase 1/2 · NCT07023731 Completed
ARV-6723 Advanced Solid Tumor Phase 1/2 · NCT07749586 Recruiting
Bavdegalutamide (ARV-110) Prostate Cancer Metastatic Phase 1/2 · NCT03888612 Completed
Rosuvastatin Healthy Phase 1 · NCT05652660 Completed
[oxoisoindolin-14C]ARV-471 Healthy Phase 1 · NCT05930925 Completed
Esomeprazole Healthy Phase 1 · NCT06275841 Completed
Zaloblideg (ARV-393) Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) Phase 1 · NCT06393738 Recruiting
[phenyl-14C]ARV-471 Healthy Phase 1 · NCT05930925 Completed

Also used in these trials (approved or third-party drugs, not ARVN's own candidates): Letrozole, Fulvestrant, Pembrolizumab, Palbociclib, Ribociclib, Anastrozole, Abemaciclib, Itraconazole, Midazolam Hydrochloride, Glofitamab, Dabigatran Etexilate, Carbamazepine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ARVN holds $558.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.4M/quarter from operations, an estimated runway of 57.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARVN files for a raise →

👥 Who Owns ARVN

Insiders 4.3% Institutions (289 holders) 89.7% Public and other holders 6%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 8,250,864 12.60% 2026-09-30
Vanguard Portfolio Management Institution (13G, 5%+) 3,917,671 5.98% 2026-03-31
Pfizer Inc Institution (13F) 3,457,815 5.28% 2026-09-30
Shaw D.E. & Co., Inc. Institution (13F) 3,208,075 4.90% 2026-09-30
Armistice Capital, LLC Institution (13F) 2,724,000 4.16% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 2,675,327 4.09% 2026-09-30
Two Sigma Investments, LP Institution (13F) 2,354,392 3.60% 2026-09-30
State Street Corporation Institution (13F) 2,078,905 3.17% 2026-09-30
Affinity Asset Advisors, Llc Institution (13F) 2,050,000 3.13% 2026-09-30
Venrock Adviser, LLC Institution (13F) 1,952,533 2.98% 2026-09-30
John G Houston
Director · +416,200 options
Insider 1,122,183 1.71% 2026-02-27
Randy Teel
President and CEO, Director · +238,366 options
Insider 285,009 0.44% 2026-05-21

Share count 65,485,006 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-09
filed 2026-11-09
Loomis David K
Sale (S) 232 $6.36 39,961
2026-06-24
filed 2026-06-26
Kennedy Edward Moore Jr.
Award (A) 15,527 – 54,957
2026-06-24
filed 2026-06-26
Norwalk Leslie V
Award (A) 15,527 – 41,572
2026-06-24
filed 2026-06-26
Norwalk Leslie V
Option award (A) 22,714 – –
2026-06-24
filed 2026-06-26
Cunningham Everett
Award (A) 15,527 – 41,572

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-06-05 — NDA -27.1% -4.1% —

Browse all historical PDUFA outcomes →

Get the full ARVN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARVN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.